The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivekimab might reduce development of heart disease, thereby preventing new heart attacks or strokes. Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). Which treatment participants get is decided by chance. The chance of getting ziltivekimab or placebo is the same. The participant will need to inject the study medicine into a flat skin surface in there stomach, thigh, or upper arm once every month. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe. The study will last for about 2 years.

开始日期2024-06-25

申办/合作机构

Novo Nordisk A/S

[+1]

NCT06263244

/ Not yet recruiting临床3期IIT

Specifying the Anti-inflammatory Effects of Ziltivekimab With Diverse Imaging Modalities and In-depth Cellular Phenotyping

The goal of this randomized, double blind, placebo controlled trial is to study whether ziltivekimab therapy reduces arterial wall inflammation as assessed by imaging, and reduces the systemic inflammatory tone as assessed by circulating monocytes, inflammatory biomarkers and proteomics.

开始日期2024-04-01

申办/合作机构-

NCT06200207

/ Recruiting临床3期

Effects of Ziltivekimab Versus Placebo on Heart Failure Symptoms and Physical Function in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation

The study is being done to see if ziltivekimab can be used to treat participants living with heart failure and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (inactive substance that looks like the study medicine but does not contain any medicine). The treatment participants get is decided by chance. Participant's chance of getting ziltivekimab or placebo is the same. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe. The study is expected to last for up to 1 year and 4 months.

开始日期2024-04-01

申办/合作机构

Novo Nordisk A/S

100 项与 Ziltivekimab 相关的临床结果

登录后查看更多信息

100 项与 Ziltivekimab 相关的转化医学

登录后查看更多信息

100 项与 Ziltivekimab 相关的专利（医药）

登录后查看更多信息

项与 Ziltivekimab 相关的文献（医药）

2025-08-01·ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Direct Interleukin-6 Inhibition Blunts Arterial Thrombosis by Reducing Collagen-Mediated Platelet Activation

Article

作者: Beer, Jürg H. ; Liberale, Luca ; Montecucco, Fabrizio ; Unkelbach, Leonhard Paul ; Ministrini, Stefano ; Lüscher, Thomas F. ; Niederberger, Rebecca ; Kirmes, Kilian ; Han, Jiaying ; Camici, Giovanni G. ; Tirandi, Amedeo ; Bengs, Susan ; Bongiovanni, Dario ; Puspitasari, Yustina M. ; Libby, Peter

BACKGROUND::

Recent clinical trials demonstrated a reduction in biomarkers of thrombosis and inflammation in patients with very high cardiovascular risk treated with the anti–IL-6 (interleukin 6) monoclonal antibody ziltivekimab. However, if and how direct IL-6 inhibition exerts antithrombotic effects remains unknown. This translational project aimed to investigate the effect of direct IL-6 inhibition on experimental arterial thrombus formation and its underlying cellular mechanisms.

METHODS::

Three-month-old C57BL/6J male and female mice received very low dose lipopolysaccharide for 4 weeks; in addition to lipopolysaccharide, during the fourth week, mice were randomized to receive either anti-mouse IL-6 monoclonal antibody 200 μg or IgG1 isotype control. Thrombosis of the right common carotid artery was induced by endothelial-targeted laser injury. Coagulation factors and platelet reactivity were assessed in treated mice and controls. Platelets were isolated from whole blood and their reactivity to different chemical stimuli was measured by fluorescence-activated cell sorting. Additionally, whole blood samples from patients with a history of percutaneous coronary intervention were incubated ex vivo with either ziltivekimab biosimilar or IgG1 isotype control. Platelet reactivity at rest and in response to diverse chemical stimuli was quantified by fluorescence-activated cell sorting.

RESULTS::

Mice with low-grade chronic inflammation treated with anti–IL-6 monoclonal antibody displayed significantly blunted thrombus formation, without any significant difference in coagulation factors. Ex vivo stimulation with Collagen-rP (collagen-related peptide) significantly activated platelets isolated from control mice but not those obtained from mice treated with anti–IL-6 monoclonal antibody. Similarly, platelet reactivity from patients with previous percutaneous coronary intervention fell significantly after ex vivo treatment with ziltivekimab biosimilar.

CONCLUSIONS::

Direct IL-6 inhibition blunts thrombus formation by reducing collagen-induced platelet activation. These findings offer a potential mechanistic explanation for the results observed in the RESCUE trial and support the rationale of the ongoing ZEUS trial (Ziltivekimab Cardiovascular Outcome Study).

2024-12-01·Current Atherosclerosis Reports

“Anti-inflammatory Therapies in Atherosclerosis – Where are we going?”

Review

作者: Budoff, Matthew ; Iskander, Beshoy ; Kambalapalli, Soumya ; Roy, Sion K ; Krishnan, Srikanth ; Lakshmanan, Suvasini ; Ichikawa, Keishi ; Punnanithinont, Natdanai

PURPOSE OF REVIEW:

Inflammation has been commonly known for the past decade as a part of the pathophysiology of atherosclerosis, along with lipid accumulation. However, some patients with optimized lipid-lowering therapy still have elevated inflammatory biomarkers. Anti-inflammation therapies were developed to eradicate this residual risk. We summarized the primary inflammatory pathway and recent clinical trials in anti-inflammation therapies.

RECENT FINDINGS:

Colchicine Cardiovascular Outcomes Trial (COLCOT) and LoDoCo2 (Colchicine Reduces Risk of Major Cardiovascular Events in Chronic Coronary Disease) found that low-dose colchicine significantly reduced cardiovascular death, myocardial infarction (MI), ischemic stroke and coronary revascularization in patients with recent MI within 30 days and chronic coronary disease respectively. The US Food and Drug Administration approved low-dose colchicine in 2023 for patients with established atherosclerotic cardiovascular disease (ASCVD). However, its use was limited for chronic kidney disease (CKD) patients. Reduction in Inflammation in Patients with Advanced Chronic Renal Disease Utilizing Antibody Mediated Interleukin-6 Inhibition (RESCUE) was conducted using Ziltivekimab, an IL-6 ligand monoclonal antibody and found that it significantly reduced high-sensitivity C-reactive protein, an inflammatory surrogate marker. There is an ongoing phase-3 clinical trial, Ziltivekimab Versus Placebo Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease, Chronic Kidney Disease, and Systemic Inflammation trial (ZEUS), which will be essential for further anti-inflammation therapy for patients with CKD. Numerous clinical trials have investigated anti-inflammation therapies. Colchicine is by far the only one that has the potential to be widely used due to its cost-effectiveness. Further research is needed on other novel anti-inflammation therapies and their real-world implementation.

2024-06-01·Current opinion in lipidology

C-reactive protein, pharmacological treatments and diet: how to target your inflammatory burden

Review

作者: Bay, Benjamin ; Arnold, Natalie ; Waldeyer, Christoph

Purpose of review:

This article focuses on pharmacological agents as well as dietary changes aimed at the reduction of the inflammatory burden measured by circulating C-reactive protein concentrations.

Recent findings:

Over the last years, repurposed as well as new anti-inflammatory agents have been investigated in outcome trials in the cardiovascular field. Currently, a specific inhibition of the inflammatory cascade via the interleukin-6 ligand antibody ziltivekimab is being explored in large-scale outcome trials, after the efficacy of this agent with regard to the reduction of inflammatory biomarkers was proven recently. Next to the investigated pharmacological agents, specific dietary patterns possess the ability to improve the inflammatory burden. This enables patients themselves to unlock a potential health benefit ahead of the initiation of a specific medication targeting the inflammatory pathway.

Summary:

Both pharmacological agents as well as diet provide the opportunity to improve the inflammatory profile and thereby lower C-reactive protein concentrations. Whilst advances in the field of specific anti-inflammatory treatments have been made over the last years, their broad implementation is currently limited. Therefore, optimization of diet (and other lifestyle factors) could provide a cost effective and side-effect free intervention to target low-grade vascular inflammation.

项与 Ziltivekimab 相关的新闻（医药）

2025-05-20

·Firstwordpharma

Tourmaline plans CV outcomes study for quarterly dosed IL-6 inhibitor

Tourmaline Bio on Tuesday released the first results from a Phase II study of its long-acting anti-IL-6 monoclonal antibody pacibekitug, with the findings supporting quarterly dosing of the drug in a potential late-stage trial for atherosclerotic cardiovascular disease (ASCVD). "We are thrilled with the data…and the remarkable consistency of signal across all endpoints evaluated," remarked CEO Sandeep Kulkarni.However, Tourmaline's shares slipped around 4% on Tuesday, as investors digested the data in the context of the high placebo response and Novo Nordisk's similar IL-6 inhibitor ziltivekimab.The mid-stage TRANQUILITY study is evaluating quarterly and monthly subcutaneous dosing of pacibekitug in 143 patients with elevated high-sensitivity C-reactive protein (hs-CRP), a biomarker associated with elevated cardiovascular risk, and chronic kidney disease (CKD) stage 3 or 4. "All active arms achieved rapid, deep and durable reductions in hs-CRP, and overall incidence rates of adverse events and serious adverse events were comparable between pacibekitug and placebo," Kulkarni added.High placebo responseTop-line results showed that all doses of pacibekitug achieved the trial's primary endpoint of median time-averaged percent change in hs-CRP through day 90 with "high statistical significance" versus placebo. In participants that received Tourmaline's drug at a dose of 50 mg quarterly, the median time-averaged percent change in hs-CRP through day 90 was 86%, while it was 85% and 75% in the pacibekitug 15 mg monthly and 25 mg quarterly arms, respectively, compared to 15% for placebo. In Novo's mid-stage RESCUE trial, a monthly 30 mg dose of ziltivekimab led to a 92% mean reduction in levels of hsCRP after 12 weeks, compared to 4% for placebo.Tourmaline added that for TRANQUILITY's key secondary goal of the percentage of participants achieving time-averaged hs-CRP below 2 mg/L through day 90, the 15 mg monthly cohort came out on top, with a rate of 88%, compared to 26% for placebo. In the other two arms, the rates were 81% and 80%, respectively for pacibekitug 25 mg quarterly and 50 mg quarterly.Hopes on quarterly dosing"This is the first time that pacibekitug or any IL-6 inhibitor has been tested in a clinical trial with quarterly dosing," noted Kulkarni, something he suggested "has the potential to enhance patient adherence and ultimate clinical benefit."Tourmaline indicated that the cumulative incidence of any serious adverse event (AE) was 10% in the pooled pacibekitug group, compared with 11% in the placebo arm. While rates of serious infection were also similar between pacibekitug and placbo, all four cases associated with the drug occurred in the 25 mg quarterly dosing group, where there was also one death from COVID-19."Given the strength of the data, we look forward to accelerating development of pacibekitug within atherosclerotic cardiovascular disease and abdominal aortic aneurysm," Kulkarni said. Tourmaline indicated that it expects to provide further information on a potential Phase III cardiovascular outcomes trial in ASCVD later in 2025, while initiating a proof-of-concept study in patients with abdominal aortic aneurysm in the second half.

临床结果临床2期AHA会议

2025-04-16

·药研网

IL-6的"双刃剑"效应：从免疫调控到疾病驱动的分子密码

IL-6靶点介绍白细胞介素-6，简称白介素-6( IL-6), 是一种功能广泛得多效性细胞炎症因子，属于白细胞介素家族中的重要成员，影响多种疾病的发病机制，包括自身免疫性疾病、慢性炎症和癌症。IL-6是一个小分子糖蛋白，分子量为 19~28 kDa，由184个氨基酸形成四个α螺旋结构，通常以单体形式存在，它是由纤维母细胞、单核/巨噬细胞、T淋巴细胞、B淋巴细胞、上皮细胞、角质细胞，以及多种瘤细胞所产生。IL-6基因位于人类染色体7p21，通常在受到感染、组织损伤或免疫信号激活时转录并表达。NF-kB和STAT3是调控其基因表达的关键转录因子，在炎症和应激状态下发挥作用。IL-6与多种疾病相关健康人血液中，IL-6的浓度非常低，约为1-5皮克/毫升。但炎症状态下，IL-6的浓度会急剧上升，如败血症患者中的浓度可达到微克/毫升级别。一些自身免疫病如类风湿性关节炎（RA）、克罗恩病和系统性红斑狼疮等都有较高的IL-6浓度。01自身免疫性疾病类风湿性关节炎（RA）：IL-6通过激活JAK/STAT和MAPK信号通路，促进关节滑膜炎症和骨破坏，同时sIL-6R水平升高加剧反式信号传导，导致慢性炎症。克罗恩病：IL-6异常表达导致肠道炎症，招募免疫细胞并释放炎症介质，加剧肠道损伤。系统性红斑狼疮：IL-6促进自身抗体产生，激活B细胞和T细胞，加重免疫紊乱和器官损伤。其他慢性炎症性疾病：如卡斯尔曼病（Castleman病）、贝赫切特病（Behçet病）、系统性幼年特发性关节炎等。02肿瘤相关（1）血液系统肿瘤多发性骨髓瘤：IL-6促进浆细胞异常增殖，与晚期病情和预后相关；淋巴瘤：IL-6通过旁分泌作用刺激肿瘤细胞生长，如霍奇金病、非霍奇金淋巴瘤。（2）实体瘤卵巢癌：IL-6通过反式信号形成促癌微环境，抑制化疗敏感性。乳腺癌：IL-6促进癌细胞增殖、转移，sIL-6R可作为预后标志物。肝癌：HBV感染中IL-6促进肝癌进展，其水平与癌症易感性相关03其他疾病IL-6也与心血管、神经系统、病毒/细菌感染等相关。IL-6/IL-6R信号通路的机制与调控IL-6的信号传导机制涉及其与受体（IL-6R）和共受体gp130的结合。IL-6通过经典信号传导、反式信号传导以及转呈现等多种途径激活细胞内信号通路，以实现对细胞功能的调控。IL-6R是一种80kDa的I型跨膜蛋白，有跨膜（mIL-6R）和可溶性（sIL-6R）两种形式。吉满生物根据市场需求和研究现状，推出IL-6反式信号传导报告基因检测细胞系，充分满足靶向IL-6不同方向的药物研发需求，助力药物临床申报。（咨询吉满客服同微信：18916119826）01IL-6信号转导模式经典途径-抗炎（图A）：IL-6结合膜型IL-6R（mIL-6R）和gp130，激活JAK/STAT等通路，调控急性期反应、炎症消退及稳态功能。反式信号转导-促炎（图B）：mIL-6R在细胞膜上被金属蛋白酶如ADAM17截切，形成位于细胞质中的片段，成为sIL-6R（可溶性白细胞介素-6受体）。IL-6与sIL-6R结合后激活膜gp130，扩大信号范围，过度激活会导致慢性炎症、自身免疫病及癌症。反式呈递（图C）：IL-6-mIL-6R复合物直接激活靶细胞gp130，促进致病性Th17反应。02下游信号通路JAK/STAT3通路：STAT3磷酸化调控基因表达，影响细胞增殖、存活及免疫应答。SHP2-MAPK/NF-κB通路：激活促炎和促生存信号。YAP-NOTCH通路：参与组织再生和癌症进展。03调控机制microRNAs对IL-6表达的调控：microRNAs可通过抑制或增强IL-6表达，影响癌症细胞行为和肿瘤微环境，在多种癌症中形成复杂的基因调控网络，为癌症治疗提供潜在的治疗靶点。IL-6的负反馈调节机制：IL-6效应信号的激活还会引发负反馈调节。SOCS3和PIAS等负调控因子可维持细胞内环境稳定。例如，STAT3激活会诱导SOCS3蛋白表达，结合gp130和JAKs的磷酸化结构域，使其降解，从而对IL-6信号进行负反馈调节。IL-6生物学功能与临床药物IL-6信号失调与慢性炎症、自身免疫病及癌症密切相关，持续激活促进肿瘤发生、免疫逃逸及转移。靶向IL-6/IL-6R通路（如托珠单抗）或调控分子（如miRNA、SOCS3）成为潜在治疗策略。药物类别包括针对特定细胞因子或细胞因子受体的单克隆抗体和重组蛋白，以及调节受体信号传导活性或与JAK相关的细胞内机制的小分子干预措施。目前全球有4款药物获批上市，包括靶向IL-6R的托珠单抗（Tocilizumab）、Sarilumab、和萨特利珠单抗以及靶向IL-6的司妥昔单抗。其他在研的IL-6/6R拮抗剂已进入临床或申报阶段，包括优时比的olokizumab、诺和诺德的ziltivekimab等已进入关键3期临床，其中olokizumab用于治疗RA疾病正在进行上市申请。其中Tocilizumab通过阻断IL-6信号通路显著缓解炎症和关节损伤，成为RA治疗的重要药物，除RA外，该药物还已获批全身型幼年特发性关节炎（sJIA）、巨细胞动脉炎（GCA）、多关节型幼年特发性关节炎和细胞因子释放综合征（CRS）四大适应症，展现出广泛的临床价值。由于上市时间早应用广泛，托珠单抗销售额遥遥领先，受益于用于新冠治疗的获批，曾在2021年达到销售峰值39.6亿美元，成为IL-6靶点领域的“重磅炸弹”药物。 Olokizumab最初由优时比公司研发，是一款靶向IL-6的人源化单抗。后来在2013年转让给了俄罗斯药企R-Pharm。2021年12月，Olokizumab首次在俄罗斯获批上市，商品名为 Artlegia®，用于治疗中重度类风湿关节炎（RA）（对传统DMARDs反应不足的患者）。2023年，中国国家药监局（NMPA）受理了Olokizumab的上市申请，适应症为RA，目前仍在审评中。全球部分IL-6/IL-6R的药物开发情况总结如下：总结IL-6作为关键的炎症因子，在免疫调节、感染应答、自身免疫性疾病等多个生理和病理过程中发挥着核心作用。近年来，随着对IL-6信号通路，尤其是其经典通路与反式通路（trans-signaling）机制的深入理解，靶向IL-6/IL-6R的拮抗剂已在类风湿关节炎、NMOSD等疾病中取得显著疗效。尤其是针对IL-6反式通路的抑制剂，被认为在控制慢性炎症、肿瘤微环境调控以及多种自身免疫疾病中拥有更精准、更安全的治疗潜力。目前国内外还有多家药企布局在IL-6/IL-6R拮抗剂，开拓新的适应症。未来，IL-6靶向治疗不仅将在适应症拓展上持续突破，也有望与其他免疫疗法联手，打开炎症性疾病治疗的新篇章。用心做好细胞，为更好的靶向药吉满生物根据市场需求和研究现状，推出IL-6报告基因检测细胞系，充分满足药物研发需求，助力药物临床申报。（咨询吉满客服同微信：18916119826）产品列表分类货号产品名称细胞GM-C39792GP130 Reporter 293 Cell LineGM-C01951H_IL-6 Reporter 293 Cell Line数据展示GM-C39792：GP130 Reporter 293 Cell Line使用IL-6/IL-6R药物激活验证结果联系我们吉满生物(Genomeditech)成立于2011年，是专业从事生物科技服务和前沿技术研发的高新技术企业。吉满生物专注为生物药开发赋能，自主创立了国内知名的细胞系品牌-DDXCELL，目前已布局近400个热门靶向药靶点，超1000株现货单克隆细胞系，涵盖GPCR、细胞因子、免疫检查点、TAA等多领域，做到进口细胞的国产替代。此外，吉满生物还可在药物研发进程中提供一系列抗体、蛋白产品，旨在为客户提供高效的研发工具和解决方案!扫码咨询扫码找现货

2025-01-22

·PRNewswire

Chronic Heart Failure Market to Observe Stunning Growth at a CAGR of 10% by 2034 Owing to Strong Uptake of Entresto and approved SGLT2 Inhibitors along with Emergence of New Class of Therapies | DelveInsight

Several leading classes of therapies are exploring diverse mechanisms of action to treat CHF, including SGLT2 inhibitors, cardiac myosin activators, myeloperoxidase inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, cell therapies, and more. This growing focus is expected to drive the chronic heart failure market forward. In summary, the existing blockbuster therapies such as Entresto, recently approved SGLT2 inhibitors, and Soluble guanylate cyclase (sGC) stimulators, along with emerging cell therapies, peptides, monoclonal antibodies, and small molecules, together have the potential to drive the existing market along with securing a significant market share upon introduction of new entrants to the CHF treatment landscape. LAS VEGAS, Jan. 22, 2025 /PRNewswire/ -- DelveInsight's Chronic Heart Failure Market Insights report includes a comprehensive understanding of current treatment practices, chronic heart failure emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan]. Key Takeaways from the Chronic Heart Failure Market Report According to DelveInsight's analysis, the market size for chronic heart failure was found to be approximately USD 5.5 billion in the US in 2023. Among the 7MM, the US contributed the largest market share of the total CHF market size and will continue to experience a steep rise in the market size throughout the forecast period. As per DelveInsight's estimate, the total diagnosed prevalent cases of CHF in the 7MM were approximately 20 million in 2023. Heart failure with preserved ejection fraction (HFpEF) contributed to most of the cases. Within class-specific diagnosed prevalence of Heart failure, NYHA class II and class III contribute the maximum. Established chronic heart failure companies with approved therapies in the market are Novartis, Otsuka, Boehringer Ingelheim/Eli Lilly, Bayer/Merck, Amgen/Servier, scPharmaceuticals, and Lexicon Pharmaceuticals/Viatris. In addition, Daiichi Sankyo and American Regent are targeting adult patients with heart failure who are iron deficient. Among all the approved therapies, Novartis and Otsuka's Entresto, approved since 2015 in the US, is still the leading therapy generating more than USD 4 billion in the 7MM in 2023. Among, Eli Lilly's Jardiance and AstraZeneca's Farxiga, both SGLT2 inhibitors, Farxiga is the leading prescribed SGLT2 inhibitor globally by volume Leading chronic heart failure companies developing emerging therapies, such as Cytokinetics, Bayer, Eli Lilly, BioCardia, Mesoblast, Tenax Therapeutics, Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Intra-Cellular Therapies, Cardurion Pharmaceuticals, Rivus Pharmaceuticals, and others are developing novel chronic heart failure drugs that can be available in the chronic heart failure market in the coming years. The promising chronic heart failure therapies in the pipeline include Omecamtiv Mecarbil, KERENDIA (finerenone), Tirzepatide (LY3298176), CardiAMP Cell Therapy, Ziltivekimab (NN6018), REVASCOR (rexlemestrocel-L), Levosimendan (TNX-103), Semaglutide, Balcinrenone (AZD9977) + dapagliflozin, Mitiperstat (AZD4831), Vicadrostat (BI 690517) + Empagliflozin, Cimlanod (CXL-1427/BMS-986231), Lenrispodun (ITI - 214), CRD-740, HU6, and others. In October 2024, Viatris entered into an exclusive licensing agreement with Lexicon Pharmaceuticals for INPEFA (sotagliflozin) in all markets outside of the US and EU. In September 2024, Bayer presented the late-breaking data of Phase III FINE-HEART findings of KERENDIA (finerenone) during a Hot Line session at the European Society of Cardiology (ESC) Congress 2024. In May 2024, Eli Lilly and Company committed an additional USD 5.3 billion manufacturing investment in the company's newest Indiana site to boost API production for tirzepatide and pipeline medicines. AstraZeneca expects the data of the Phase III BalanceD-HF trial of balcinrenone (AZD9977) + dapagliflozin for heart failure in 2025. Discover which therapies are expected to grab the major chronic heart failure market share @ Chronic Heart Failure Market Report Chronic Heart Failure Overview Chronic heart failure is a long-term condition in which the heart's ability to pump blood efficiently is reduced, leading to inadequate circulation of oxygen and nutrients to meet the body's needs. The primary causes of CHF include coronary artery disease, high blood pressure, diabetes, cardiomyopathy, valvular heart disease, and previous heart attacks. Lifestyle factors like obesity, smoking, excessive alcohol consumption, and a sedentary lifestyle can also contribute to its development. The symptoms of CHF vary in severity and may include persistent fatigue, shortness of breath, swelling in the legs, ankles, or abdomen, rapid or irregular heartbeat, and difficulty exercising. Advanced cases can lead to severe fluid retention, wheezing, and an inability to carry out daily activities. Diagnosis typically involves a comprehensive medical history review and a physical examination, followed by tests like an ECG to assess heart rhythm, echocardiography to evaluate heart structure and function, blood tests, chest X-rays, and stress tests. Early diagnosis and management are crucial to improving quality of life and preventing complications. Chronic Heart Failure Epidemiology Segmentation The chronic heart failure epidemiology section provides insights into the historical and current chronic heart failure patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The chronic heart failure market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Diagnosed Prevalent Cases of Heart Failure Gender-specific Cases of Heart Failure Ejection Fraction-specific Cases of Heart Failure New York Heart Association (NYHA) Class-specific Cases of Heart Failure Type-specific Cases of Heart Failure Age-specific Cases of Heart Failure Chronic Heart Failure Treatment Market Current treatments for heart failure primarily rely on angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta-blockers, and diuretics. Additional therapies, such as aldosterone antagonists, amiodarone, antiplatelets, anticoagulants, calcium channel blockers, and nitrates, are also utilized in managing the condition. Most treatment regimens involve a combination of therapies, with beta-blockers being among the most commonly prescribed. Among the approved treatments, Novartis' ENTRESTO has emerged as a leading drug in the congestive heart failure market. Initially slow to gain traction, ENTRESTO has become one of Novartis' key growth drivers, with revenue expected to increase in the coming years. Following its approval for use in patients with preserved ejection fraction, ENTRESTO's market presence has grown significantly. However, ENTRESTO faces growing competition. The entry of new drugs, including SGLT2 inhibitors (such as FARXIGA and JARDIANCE) and VERQUVO, poses a challenge to ENTRESTO's dominance. Additionally, Novartis is set to lose ENTRESTO's exclusivity in the United States in 2025, raising the risk of generic competition. The company is actively engaged in several patent lawsuits to protect its position. SGLT2 inhibitors have also gained a foothold in the CHF market. Although FARXIGA and JARDIANCE are established drugs, they are relatively new in this therapeutic area. The outlook for SGLT2 inhibitors in heart failure is promising, but AstraZeneca and Lilly/Boehringer will have limited time to solidify their positions, as FARXIGA's US patent expires in 2025 and JARDIANCE's in 2028. The recently approved SGLT2 inhibitor sotagliflozin may face challenges in capturing market share from these established treatments. To know more about chronic heart failure treatment guidelines, visit @ Chronic Heart Failure Management Chronic Heart Failure Pipeline Therapies and Key Companies Omecamtiv Mecarbil: Cytokinetics KERENDIA (finerenone): Bayer Tirzepatide (LY3298176): Eli Lilly and Company CardiAMP Cell Therapy: BioCardia Ziltivekimab (NN6018): Novo Nordisk REVASCOR (rexlemestrocel-L): Mesoblast Levosimendan (TNX-103): Tenax Therapeutics Semaglutide: Novo Nordisk Balcinrenone (AZD9977) + dapagliflozin: AstraZeneca Mitiperstat (AZD4831): AstraZeneca Vicadrostat (BI 690517) + Empagliflozin: Boehringer Ingelheim Cimlanod (CXL-1427/BMS-986231): Bristol Myers Squibb Lenrispodun (ITI - 214): Intra-Cellular Therapies CRD-740: Cardurion Pharmaceuticals HU6: Rivus Pharmaceuticals Discover more about chronic heart failure drugs in development @ Chronic Heart Failure Clinical Trials Chronic Heart Failure Market Dynamics The chronic heart failure market dynamics are expected to change in the coming years. An increasing prevalence of cardiovascular diseases, fueled by aging populations and lifestyle-related risk factors such as obesity, hypertension, and diabetes, has significantly raised the demand for effective CHF treatments. Advances in medical technology, including innovative drug therapies, cardiac devices, and regenerative medicine, are expanding treatment options and improving patient outcomes. Growing awareness about heart health and early diagnosis, supported by government and non-government initiatives, is also boosting market expansion. Additionally, the rising focus on personalized medicine and the development of therapies targeting the underlying molecular mechanisms of CHF are creating lucrative opportunities. The increasing healthcare expenditure and the availability of reimbursement policies in developed and emerging economies further bolster the market's growth trajectory. Furthermore, potential therapies are being investigated for the treatment of chronic heart failure, and it is safe to predict that the treatment space will significantly impact the chronic heart failure market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the chronic heart failure market in the 7MM. However several factors may impede the growth of the chronic heart failure market. A key challenge is the underdiagnosis and delayed recognition of CHF due to overlapping symptoms with other conditions and the lack of widespread access to advanced diagnostic tools in many regions. Economic constraints, particularly in low- and middle-income countries, limit patient access to costly therapies, including advanced drugs and devices. Additionally, adherence to treatment regimens remains low due to the complexity of management protocols and the long-term nature of care, leading to suboptimal outcomes. Regulatory hurdles and lengthy approval processes for novel therapies further impede the introduction of innovative treatments. Finally, a limited understanding among general practitioners about newer guidelines and therapies reduces the referral rates to specialists, creating gaps in patient care. Addressing these barriers requires concerted efforts in education, affordability, and healthcare infrastructure. Scope of the Chronic Heart Failure Market Report Therapeutic Assessment: Chronic Heart Failure current marketed and emerging therapies Chronic Heart Failure Market Dynamics: Key Market Forecast Assumptions of Emerging Chronic Heart Failure Drugs and Market Outlook Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Chronic Heart Failure Market Access and Reimbursement Download the report to understand which factors are driving chronic heart failure market trends @ Chronic Heart Failure Market Trends Table of Contents Related Reports Chronic Heart Failure Epidemiology Forecast Chronic Heart Failure Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the chronic heart failure epidemiology trends. Chronic Heart Failure Pipeline Chronic Heart Failure Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key CHF companies, including Zensun (Shanghai) Sci & Tech, Cytokinetics, Mesoblast, Shanghai Hongyitang Biopharmaceutical Technology, Tasly Pharmaceuticals, Ionis Pharmaceuticals, Berlin Cures, CardioCell, Help Therapeutics, Eli Lilly and Company, Chong Kun Dang Pharmaceutical, Antlia Biosciences, Cardiol Therapeutics, among others. Acute Coronary Syndrome Market Acute Coronary Syndrome Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ACS companies, including Novartis, Boehringer Idorsia Pharmaceuticals, Viatris, Recardio, AstraZeneca, Faraday Pharmaceuticals, DalCor Pharmaceuticals, Roche, Jiangsu Vcare PharmaTech, CeleCor Therapeutics, Novo Nordisk, Bristol Myers Squibb, Johnson & Johnson Innovative Medicine, CellProthera, BioCardia, Kancera, Amgen, Arrowhead Pharmaceuticals, Abcentra , among others. Acute Coronary Syndrome Pipeline Acute Coronary Syndrome Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key acute coronary syndrome companies, including Janssen Research & Development, LLC, DalCor Pharmaceuticals, Hyloris Pharmaceuticals, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床3期上市批准引进/卖出

100 项与 Ziltivekimab 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性心肌梗塞	临床3期	美国	Novo Nordisk A/S	2024-06-25
急性心肌梗塞	临床3期	中国	Novo Nordisk A/S	2024-06-25
急性心肌梗塞	临床3期	日本	Novo Nordisk A/S	2024-06-25
急性心肌梗塞	临床3期	阿根廷	Novo Nordisk A/S	2024-06-25
急性心肌梗塞	临床3期	澳大利亚	Novo Nordisk A/S	2024-06-25
急性心肌梗塞	临床3期	巴西	Novo Nordisk A/S	2024-06-25
急性心肌梗塞	临床3期	保加利亚	Novo Nordisk A/S	2024-06-25
急性心肌梗塞	临床3期	加拿大	Novo Nordisk A/S	2024-06-25
急性心肌梗塞	临床3期	捷克	Novo Nordisk A/S	2024-06-25
急性心肌梗塞	临床3期	丹麦	Novo Nordisk A/S	2024-06-25

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03926117 (RESCUE, Pubmed) 人工标引	临床2期	炎症 \| 慢性肾病 C-reactive Protein Expression	261	Ziltivekimab 7.5 mg	鹽範鬱憲繭鏇夢鹹襯築(襯範繭顧夢遞壓積窪構) = 選夢繭繭鏇簾網醖獵繭範鏇顧鹽鑰膚繭艱壓齋 (顧淵觸淵淵壓網顧鬱繭 )	积极	2024-01-01
				Ziltivekimab 15 mg	鹽範鬱憲繭鏇夢鹹襯築(襯範繭顧夢遞壓積窪構) = 襯鬱鏇遞廠艱構鏇蓋淵範鏇顧鹽鑰膚繭艱壓齋 (顧淵觸淵淵壓網顧鬱繭 )
NCT04626505 (RESCUE-2, Pubmed \| J Cardiol)	临床2期	动脉粥样硬化 high-sensitivity C-reactive protein (hsCRP)	-	Ziltivekimab 15mg	願範窪壓夢衊鹹遞醖簾(衊網餘窪繭獵積艱願壓) = 鬱餘選齋廠膚鬱顧繭餘糧簾鬱廠醖壓糧觸齋鹹 (醖簾壓衊網鏇艱廠遞簾 )	积极	2023-10-01
				Ziltivekimab 30mg	願範窪壓夢衊鹹遞醖簾(衊網餘窪繭獵積艱願壓) = 網鏇顧鹽鏇鏇鹽衊鏇鏇糧簾鬱廠醖壓糧觸齋鹹 (醖簾壓衊網鏇艱廠遞簾 )
NCT03926117 (RESCUE \| RESCUE Trial, CTgov)	临床2期	炎症 \| 慢性肾病	264	Ziltivekimab (Placebo)	願觸範襯壓餘餘鹽選鏇(淵廠糧鬱夢遞願蓋窪積) = 醖鑰網醖選鑰簾選簾憲艱衊觸積簾醖衊簾簾夢 (艱鏇醖構壓願繭蓋鏇醖, 襯餘鑰鏇積襯夢簾鑰鹹 ~ 膚願蓋淵繭醖餘壓獵網) 更多	-	2023-08-09
				Ziltivekimab (Ziltivekimab 7.5 mg)	願觸範襯壓餘餘鹽選鏇(淵廠糧鬱夢遞願蓋窪積) = 餘襯艱廠築糧憲鏇淵夢艱衊觸積簾醖衊簾簾夢 (艱鏇醖構壓願繭蓋鏇醖, 選顧顧獵齋網顧構鏇鑰 ~ 觸襯廠製願積夢鹹膚艱) 更多
NCT03926117 (RESCUE Trial, ASN2021)	临床2期	慢性肾病 serum hemoglobin \| iron homeostasis \| high-sensitivity C-reactive protein	-	Ziltivekimab 7.5 mg	醖廠鹽範獵鹽鹹鑰範簾(艱齋範鏇糧顧鏇淵憲鏇) = 選夢簾窪構積夢繭憲餘廠窪夢鬱壓願窪鏇願範 (窪獵鏇糧艱糧鹽蓋願築 )	积极	2021-10-27
				Ziltivekimab 15 mg	醖廠鹽範獵鹽鹹鑰範簾(艱齋範鏇糧顧鏇淵憲鏇) = 繭鏇醖餘鹽築醖夢襯網廠窪夢鬱壓願窪鏇願範 (窪獵鏇糧艱糧鹽蓋願築 )
NCT02868229 (CTgov)	临床1/2期	贫血	61	Placebo (Placebo)	網範窪鹹襯鹽範衊窪築 = 艱糧範鏇鹹繭蓋鬱鹽鹽憲獵餘築範壓鏇積遞夢 (壓鏇鹽鹹淵糧衊簾鬱選, 淵夢餘鏇醖糧醖膚遞淵 ~ 膚願範簾廠觸範襯鑰遞) 更多	-	2021-07-30
				COR-001 (COR-001)	夢廠觸糧範觸製顧獵顧(製觸鬱糧願淵鹹鏇夢窪) = 淵襯鑰糧衊糧遞繭選鏇鏇築憲觸構積選膚顧醖 (選製選鏇網範蓋憲鏇艱, 願艱願壓簾壓夢構築鏇 ~ 齋構蓋選網鏇糧願憲網)
NCT03926117 (RESCUE, Pubmed \| Lancet)	临床2期	动脉粥样硬化	264	Placebo	醖襯鬱廠範壓願廠選蓋(網願壓夢淵範築觸積遞) = 夢範襯壓鬱夢壓選壓鏇憲夢艱繭醖衊觸顧繭願 (衊顧觸觸壓範遞願淵壓 )	积极	2021-05-14
ASN2019	临床1期	慢性肾病	12	COR-001 5 mg	簾鑰餘襯餘淵艱醖構選(繭衊廠憲遞構蓋範簾憲) = 餘鹽廠製選淵願憲醖構繭繭憲鑰繭衊蓋壓壓積 (艱積醖鑰鑰獵壓選獵憲 )	积极	2019-11-05
				COR-001 15 mg	簾鑰餘襯餘淵艱醖構選(繭衊廠憲遞構蓋範簾憲) = 夢鏇鑰築積鑰網鹽壓夢繭繭憲鑰繭衊蓋壓壓積 (艱積醖鑰鑰獵壓選獵憲 )